Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey

Basit Öğe Kaydı
dc.authorid0000-0003-2774-8601en_US
dc.authorscopusid23996235800en_US
dc.authorwosidF-6427-2011en_US
dc.contributor.authorTabak, Fehmi
dc.contributor.authorYörük, Gülşen
dc.contributor.authorKöksal, İftihar
dc.contributor.authorErdem, Hazal
dc.contributor.authorYıldız, Dilek
dc.contributor.authorİnce, Nevin
dc.contributor.authorYamazhan, Tansu
dc.contributor.authorSume, Serkan
dc.contributor.authorBatırel, Ayşe
dc.contributor.authorGünal, Özgür
dc.contributor.authorYıldız, İlknur Esen
dc.contributor.authorSırmatel, Fatma
dc.contributor.authorKoç, Meliha Merih
dc.contributor.authorÇeken, Sabahat
dc.contributor.authorBozkurt, İlkay
dc.contributor.authorGörenek, Levent
dc.contributor.authorŞener, Alper
dc.contributor.authorKöse, Şükran
dc.contributor.authorTürker, Kamuran
dc.contributor.authorİnan, Dilara
dc.contributor.authorKarabay, Oğuz
dc.contributor.authorGüner, Rahmet
dc.date.accessioned2022-09-20T13:04:02Z
dc.date.available2022-09-20T13:04:02Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
dc.description.abstractTenofovir alafenamide (TAF) is a new prodrug of tenofovir used for the treatment of HIV-1 and HBV infections. It provides more efficient intracellular tenofovir concentrations at a relatively lower dose than provided by tenofovir disoproxil fumarate (TDF). TAF is expected to have efficacy similar to that of TDF with improved safety profile.en_US
dc.identifier.citationTabak, F., Yörük, G., Köksal, İ., Erdem, H., Yıldız, D., İnce, N.,...Güner, R. (n.d.). Switching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey. https://www.webofscience.com/wos/woscc/full-record/WOS:000707188002220
dc.identifier.endpage498Aen_US
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.startpage497Aen_US
dc.identifier.urihttps://hdl.handle.net/20.500.12428/3731
dc.identifier.volume74en_US
dc.identifier.wosWOS:000707188002220
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorŞener, Alper
dc.language.isoen
dc.publisherWileyen_US
dc.relation.ispartofHepatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectTenofovir alafenamide (TAF)en_US
dc.subjectProdrugen_US
dc.subjectHIV-1en_US
dc.subjectHBV infectionsen_US
dc.titleSwitching to tenofovir alafenamide in hbv: nationwide real life data of efficacy and safety from Turkey
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Alper_Sener_KonferansOgesi.pdf
Boyut:
758.67 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Konferans Ögesi
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu